GSTM1 and anemia (phenotype): In the moderate anemia group, content of Hb was 80.27 ± 10.29 g/L, 82.93 ± 8.95 g/L, and 83.55 ± 9.97 g/L after one, two, and three months of treatment, respectively; Hb content significantly increased compared with that before treatment, 75.93 ± 8.86 g/L (p = 0.000 after one, two, and three months).